SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is trending as the community celebrates the recovery of its ticker symbol and continues to push for broader visibility while emphasizing their commitment to an organic, long-term project. Investors are actively discussing the potential for a forthcoming chart listing and rallying around a narrative of collective building to differentiate themselves from short-term memecoin scams.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is seeing significant momentum driven by CEO Andy Jassys confirmation of a massive AI infrastructure spend and a $20 billion revenue run rate for its custom silicon business, sparking optimism that it is successfully pivoting toward long-term AI dominance. Community sentiment is increasingly bullish, with traders actively discussing its strategic partnerships with Anthropic and the potential for a major valuation re-rating as AWS scales.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending following a significant multi-year cloud infrastructure deal with Anthropic to support its Claude models, signaling sustained demand for high-performance AI compute. While the partnership has fueled bullish sentiment around its expanding roster of major AI clients, traders are simultaneously debating the impact of the company's concurrent upsized debt offering and broader market volatility.

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit is currently trending as investors debate whether the recent sharp sell-off is a fundamental breakdown driven by AI-related disruption or a massive overreaction to bearish sentiment. While community sentiment is heavily divided, many are treating the pullback as a long-term opportunity to buy a profitable, high-margin leader at valuation levels not seen in years, pointing to share buyback acceleration and a strong competitive moat as key catalysts for a potential reversal.

VS Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

Investors are actively flocking to UVIX as a hedge against rising geopolitical tensions in the Middle East and concerns over oil supply disruptions following the closure of the Strait of Hormuz. The community is heavily debating whether the current market stability is a temporary lull driven by political rhetoric or a fragile calm before a significant volatility breakout, fueling intense discussion around potential black swan events.

iShares Trust - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF (IGV) is currently the focal point of a intense debate over whether the sector is experiencing a permanent structural 'SaaSpocalypse' driven by AI disruption or a prime contrarian buying opportunity. While many community members highlight deep valuation compression and signs of institutional accumulation at multi-year lows, others caution that the sector remains highly vulnerable to continued volatility and potential further downside as AI models continue to challenge traditional software business models.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is seeing heightened community discussion as investors weigh its aggressive infrastructure expansion against ongoing concerns regarding potential equity dilution from its sizable at-the-market offering. The stock is currently being closely monitored for a potential breakout as traders look for news on site energizations and new hyperscaler partnerships to confirm its competitive standing within the evolving AI and data center sector.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is experiencing heightened volatility and intense social media debate after a high-profile public endorsement from former President Trump, which has fueled a tug-of-war between retail traders banking on a government-backed "narrative tailwind" and bearish investors, including notable figures like Michael Burry, who are focusing on valuation concerns and competitive threats. The active community discussion centers on whether this presidential spotlight will act as a structural catalyst for further government contracts and a short squeeze, or if fundamental pressure from the broader software sector and repricing risks will ultimately dictate the stock's near-term direction.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

REalloys Inc. is trending as investors focus on its pivot to building a domestic heavy rare earth metallization facility designed to replace Chinese-sourced materials in U.S. defense supply chains. The community is actively debating the company's long-term potential as a critical defense contractor against concerns regarding its pre-revenue status and capital structure.

Sezzle, Inc. engages in the operation of a digital payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie G. Youakim, Killian Brackey and Paul V. Paradis on January 4, 2016 and is headquartered in Minneapolis, MN.

Sezzle Inc.

Sezzle is seeing intense market volatility and increased short interest following a board-level shakeup, with the community actively debating whether the resignation of a key board member signals deeper governance issues or a buying opportunity. Traders are heavily focused on the company's strong fundamentals and upcoming earnings as potential catalysts to trigger a short squeeze against a backdrop of ongoing institutional accumulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Greenwich LifeSciences (GLSI) Expected to Announce Quarterly Earnings on Tuesday

Greenwich LifeSciences (NASDAQ:GLSI) will be releasing earnings after the market closes on Tuesday, March 31. (View Earnings Report at...

<ul class="summary-bullets"><li>Greenwich noted that despite the absence of a placebo arm, GLSI-100 showed an annual recurrence rate below 1%, compared with about 4% in the KATHERINE trial of Kadcyla over a similar timeframe.</li><li>The company also stated that the Phase III trial results are trending in line with those from the Phase IIb trial.</li><li>Greenwich reported a reduction of up to 80% in breast cancer recurrences, while other approved products showed a reduction of 20% to 25%, the company said.</li></ul>Greenwich LifeSciences Inc. (GLSI) shares gained more than 13% in Tuesday’s pre-market trade after the company announced that its immunotherapy trial has shown a continued reduction in the rate of recurrence of breast cancer.Greenwich LifeSciences said its 250-patient Phase III breast cancer immunotherapy trial, FLAMINGO-01, showed an annual recurrence rate below 1%.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/GLSI">Greenwich LifeSciences</a> trended in the ‘extremely bullish’ territory with message volumes at ‘extremely high’ levels. GLSI was the top trending ticker on the platform at the time of writing.<h2 class="st-heading-2">Results Show About 70-80% Reduction In Recurrence Rate, Says Greenwich</h2>Greenwich noted that despite the absence of a placebo arm, GLSI-100 showed an annual recurrence rate below 1%, compared with about 4% in the KATHERINE trial of Kadcyla over a similar timeframe.The company also stated that the results of the Phase III trial are trending in line with those from the Phase IIb results. Greenwich reported a reduction of up to 80% in breast cancer recurrences, while other approved products showed a reduction of 20% to 25%, the company said.However, Greenwich stated that these Phase III trial results are still preliminary and that the final analysis may differ.The Phase III FLAMINGO-01 trial is designed to evaluate the safety and efficacy of GLSI-100 in HER2-positive breast cancer patients with residual disease or high-risk pathological complete response who have completed neoadjuvant and adjuvant trastuzumab-based therapy.<h2 class="st-heading-2">What Does Greenwich LifeSciences Do?</h2>Greenwich LifeSciences is a clinical-stage biopharmaceutical company based out of Stafford, Texas. It is currently focused on the development of GP2, which is an immunotherapy to prevent breast cancer recurrence in patients who have previously undergone surgery.<a href="https://stocktwits.com/symbol/GLSI">GLSI stock</a> is up 34% year-to-date and 134% over the past 12 months. The iShares Russell 2000 Growth ETF (IWO) is up 22% over the past 12 months, while the iShares Micro-Cap ETF (IWC) is up 40%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-says-fed-chair-powell-should-cut-rates-right-now/cZ3PPPaRIfw">Trump Says Fed Chair Powell Should Cut Rates Right Now</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is GLSI Stock Rising Today?

Greenwich LifeSciences said its Phase III breast cancer immunotherapy trial, involving 250 patients, showed a recurrence rate of under 1% per year.

Equity

Greenwich LifeSciences (NASDAQ:GLSI) Trading Up 11.6% - Should You Buy?

Greenwich LifeSciences (NASDAQ:GLSI) Trading Up 11.6% - Time to Buy...

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Down 14.7% in January

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) was the target of a significant drop in short interest in January. As of January 30th, there was short interest totaling 1,318,481 shares...

HC Wainwright Issues Positive Forecast for GLSI Earnings

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) - Stock analysts at HC Wainwright upped their Q3 2026 earnings per share estimates for Greenwich LifeSciences in a report released on...

Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 6.7% - Time to Sell?

Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Down 6.7% - Here's Why...

Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Down 6.7% - Here's What Happened

Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 6.7% - Here's What Happened...

$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium

$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium PR Newswire VANCOUVER, BC, Jan...

<ul class="summary-bullets"><li>The company is running a Phase III study known as FLAMINGO-01, which is testing GLSI-100.</li><li>The approval follows the submission of manufacturing and stability data tied to multiple production runs.</li><li>More than 1,000 patients have already been screened for FLAMINGO-01.</li></ul>Greenwich LifeSciences, Inc. (GLSI) announced on Thursday that it has cleared another regulatory step in the development of its breast cancer immunotherapy as the company advances its late-stage clinical program.&nbsp;The clinical-stage biotechnology firm is running a Phase III study known as FLAMINGO-01, which is testing GLSI-100, a therapy designed to reduce the risk of cancer returning in certain breast cancer patients.<h2 class="st-heading-2">FDA Manufacturing Clearance</h2>The company disclosed that the Food and Drug Administration (FDA) has reviewed and authorized the use of its first commercially produced batch of the GP2 drug product in the ongoing FLAMINGO-01 trial.&nbsp;Following the update,&nbsp;<a href="https://stocktwits.com/symbol/GLSI">Greenwich LifeSciences stock</a> traded over 16% higher in Thursday’s premarket. However, on Stocktwits, retail sentiment around the stock remained in ‘bearish’ territory amid ‘low’ message volume levels.&nbsp;The approval follows the submission of manufacturing and stability data tied to multiple production runs completed over the past two years.<blockquote>"With our manufacturing investments in 2023 and 2024, and now the FDA's review and approval to use the first commercial lot of finished GP2 vials in FLAMINGO-01, we have taken major steps to further de-risk the filing of a BLA in the US.”-Snehal Patel, CEO, Greenwich LifeSciences</blockquote><h2 class="st-heading-2">Trial Progress And Early Signals</h2>More than 1,000 patients have already been screened for FLAMINGO-01, with enrollment continuing at a steady pace. One treatment arm involving patients without the HLA-A*02 marker has now completed enrollment, providing a larger dataset than earlier mid-stage research.&nbsp;Preliminary observations following the initial dosing period suggest a sharp decline in recurrence rates, though the company cautioned that the findings remain early and incomplete.GLSI stock has gained over 75% higher in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ondas-retail-chatter-up-in-a-week-what-is-driving-trader-interest/cmUzw1HR4Qo">Ondas Retail Chatter Up 131% In A Week — What's Driving Trader Interest?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena.

Why Did Greenwich LifeSciences Stock Soar Pre-Market Today?

The company disclosed that the Food and Drug Administration (FDA) has reviewed and authorized the use of its first commercially produced batch of the GP2 drug product in the ongoing FLAMINGO-01 trial. 

GLSI Stock Surges Pre-Market On Clearing FDA Manufacturing Step For Its Breast Cancer Trial

The company disclosed that the Food and Drug Administration (FDA) has reviewed and authorized the use of its first commercially produced batch of the GP2 drug product in the ongoing FLAMINGO-01 trial. 


Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Acquires 1,800 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel bought 1,800 shares of the stock in a transaction dated Tuesday, January 13th. The stock was purchased at an average...

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

GLSI
Greenwich LifeSciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GLSI News

GLSIGreenwich LifeSciences Inc